Oragenics to Present at Sequire Investor Summit in Puerto Rico, Discussing Concussion and Traumatic Brain Injury Treatment.

Oragenics, a clinical-stage biotechnology company, will present at the Sequire Investor Summit 2026 in Puerto Rico. The company's lead candidate, ONP-002, is being developed as a treatment for concussion and mild traumatic brain injury. Oragenics is progressing ONP-002 through Phase 2a clinical trials in Australia, with U.S. Phase IIb trials planned to follow. The company's intranasal delivery platform has potential applications across multiple neurological conditions.